The first new Alzheimer’s drug has gained approval from the United States; this will pave way for its use in the United Kingdom. The drug which is known as Aducanumab, treats the underlying cause of the disease rather than its symptoms.
This is good news for charities as this treatment is welcomed. However, scientists aren’t certain about its impact because the trial results seems not to be accurate.
There was “substantial evidence that aducanumab reduces amyloid-beta plaques in the brain” and that this “is reasonably likely to predict important benefits to patients.The US Food and Drug Administration
The international trials of Aducanumab which involved almost 3,000 patients were stopped when analysis revealed that the drug was just a dummy drug. However, after that year, Biogen evaluated more data and confirmed that the drug worked as long as it was taken in higher doses.
You can also read: Gambia Gets Rid of Trachoma
The US company also claimed that this drug slowed cognitive decline. Aducanumab aims at destroying amyloid, a protein that develops clumps in the brain of people suffering Alzheimer’s.
Aldo Ceresa who partook in the trial noticed that he had problems differentiating between right and left. Due to this, the 68-year-old man had to stop working as a surgeon. Mr. Ceresa was given aducanumab for two years before the trial was stopped.
According to him, the drug is working for him. He said he is enjoying the benefits of the treatment as he is seeing results. Over 30 million people across the globe are thought to suffer from Alzheimer’s disease.The approval of the first new Alzheimer’s drug will help fight the disease.